
    
      To assess the single dose pharmacokinetics, safety, and tolerability of GLA5PR GLARS-NF3
      tablet 150mg administered regular die relative to GLA5PR GLARS-NF1 tablet 150mg administered
      regular diet. IP will be administered 1 tablet(150mg) once a day(QD) after evening meal.
    
  